MUTATIONAL ANALYSIS OF STRUCTURE - ACTIVITY RELATIONSHIPS IN HUMAN TUMOR NECROSIS FACTOR-ALPHA

被引:88
|
作者
YAMAGISHI, J
KAWASHIMA, H
MATSUO, N
OHUE, M
YAMAYOSHI, M
FUKUI, T
KOTANI, H
FURUTA, R
NAKANO, K
YAMADA, M
机构
[1] Research Laboratories, Dainippon Pharmaceutical Co. Ltd, 33-94, Enoki, Suita
来源
PROTEIN ENGINEERING | 1990年 / 3卷 / 08期
关键词
Cytotoxic activity; Human tumor necrosis factor-alpha; MutD mutagenesis; Oligonucleotide-directed mutagenesis; Receptor binding activity;
D O I
10.1093/protein/3.8.713
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To determine the region of human tumor necrosis factor-alpha (TNF-α), essential for cytotoxic activity against mouse L-M cells, single amino-acid-substituted TNF-α mutant proteins (muteins) were produced in Escherichia coli by protein engineering techniques. An expression plasmid for TNF-α was mutagenized by passage through an E.coli mutD5 mutator strain and by oligonucleotide-directed mutagenesis. Approximately 100 single amino-acid-substituted TNF-α muteins were produced and assayed for cytotoxic activity. The cytotoxic activities of purified TNF-α muteins, e.g. TNF-31T, -32Y, -82D, -85H, -115L, -141Y, -144K and -146E, were < 1% of that of parent TNF-α. These results indicate that the integrity of at least four distinct regions of the TNF-α molecule is required for full biological activity. These regions are designated as follows: region I, from position 30 to 32; region II, from position 82 to 89; region III, from position 115 to 117; region FV, from position 141 to 146. In addition, TNF-141Y could not completely compete with parent TNF-α for binding to the receptor. This demonstrates that region IV, and at least aspartk acid at position 141, must be involved in the TNF receptor binding site. © 1990 Oxford University Press.
引用
收藏
页码:713 / 719
页数:7
相关论文
共 50 条
  • [41] Tumor necrosis factor-alpha and disease activity in patients with systemic lupus erythematosus
    Borodin, AG
    Baranov, AA
    Nassonov, EL
    Klukvina, NG
    Krylov, VL
    JOURNAL OF RHEUMATOLOGY, 2001, 28 : 48 - 48
  • [42] Myelin contains neutral sphingomyelinase activity that is stimulated by tumor necrosis factor-alpha
    Chakraborty, G
    Ziemba, S
    Drivas, A
    Ledeen, RW
    JOURNAL OF NEUROSCIENCE RESEARCH, 1997, 50 (03) : 466 - 476
  • [43] Obesity, tumor necrosis factor-alpha and tumor necrosis factor-alpha-308 polymorphism in normal pregnancy
    Donnelly, J
    Cooley, S
    Balding, J
    Murphy, C
    Walsh, T
    Smith, O
    Geary, M
    Mahon, CMC
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 193 (06) : S160 - S160
  • [44] Antiproliferative activity of shark cartilage with and without tumor necrosis factor-alpha in human umbilical vein endothelium
    McGuire, TR
    Kazakoff, PW
    Hoie, EB
    Fienhold, MA
    PHARMACOTHERAPY, 1996, 16 (02): : 237 - 244
  • [45] SYNTHESIS AND EXPRESSION OF A GENE FOR HUMAN TUMOR NECROSIS FACTOR-ALPHA (TNF-α)
    王平
    徐贤秀
    唐伟
    王启松
    朱德煦
    ChineseJournalofCancerResearch, 1992, (02) : 16 - 22
  • [46] MOLECULAR-WEIGHT OF RECOMBINANT HUMAN-TUMOR NECROSIS FACTOR-ALPHA
    ARAKAWA, T
    YPHANTIS, DA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1987, 262 (16) : 7484 - 7485
  • [47] Specific suppression of human tumor necrosis factor-alpha synthesis by antisense oligonucleotides
    Hartmann, G
    Krug, A
    Eigler, A
    Endres, S
    GASTROENTEROLOGY, 1996, 110 (04) : A1205 - A1205
  • [48] TUMOR NECROSIS FACTOR-ALPHA INDUCES INVASIVENESS OF HUMAN SKIN FIBROBLASTS INVITRO
    SCHIRREN, CG
    SCHARFFETTER, K
    HEIN, R
    BRAUNFALCO, O
    KRIEG, T
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1990, 94 (05) : 706 - 710
  • [49] ROLE OF SINGLE DISULFIDE IN RECOMBINANT HUMAN-TUMOR NECROSIS FACTOR-ALPHA
    NARACHI, MA
    DAVIS, JM
    HSU, YR
    ARAKAWA, T
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1987, 262 (27) : 13107 - 13110
  • [50] Specific suppression of human tumor necrosis factor-alpha synthesis by antisense oligodeoxynucleotides
    Hartmann, G
    Krug, A
    Eigler, A
    Moeller, J
    Murphy, J
    Albrecht, R
    Endres, S
    ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1996, 6 (04): : 291 - 299